Evidence map›Paper›PMID 29088224›Full record

ArticlePloS one2017

Vaccine adjuvant MF59 promotes the intranodal differentiation of antigen-loaded and activated monocyte-derived dendritic cells.

Rossella Cioncada, Marcella Maddaluno, Hoa Thi My Vo, Matthew Woodruff, Simona Tavarini, Chiara Sammicheli, Marco Tortoli, Alfredo Pezzicoli, Ennio De Gregorio, Michael C Carroll and 2 more

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
31citing papers in PubMed, 1 pooled it
2.0field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

31 citing papers in PubMed, 1 synthesis or guideline pooled it, 52 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Review
  9. Review
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Formulation and Delivery Technologies for mRNA Vaccines.Current topics in microbiology and immunology · 2022
    Article
  17. Review
  18. Article
  19. Use of Protamine in Nanopharmaceuticals-A Review.Nanomaterials (Basel, Switzerland) · 2021
    Review
  20. Manganese salts function as potent adjuvants.Cellular & molecular immunology · 2021
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 2 institutions in 2 countries.

Rossella CioncadaGSK Vaccines, Siena, Italy.
Marcella MaddalunoGSK Vaccines, Siena, Italy.
Hoa Thi My VoGSK Vaccines, Siena, Italy.
Matthew WoodruffBoston Children's Hospital, Harvard Medical School, Boston, MA, United States of America.
Simona TavariniGSK Vaccines, Siena, Italy.
Chiara SammicheliGSK Vaccines, Siena, Italy.
Marco TortoliGSK Vaccines, Siena, Italy.
Alfredo PezzicoliGSK Vaccines, Siena, Italy.
Ennio De GregorioGSK Vaccines, Siena, Italy.
Michael C CarrollBoston Children's Hospital, Harvard Medical School, Boston, MA, United States of America.
Ugo D'OroGSK Vaccines, Siena, Italy.
Diego PiccioliGSK Vaccines, Siena, Italy.ORCID http://orcid.org/0000-0002-5809-4455
Toscana Life Sciences · ITBoston Children's Hospital · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

MF59 is an oil-in-water emulsion adjuvant approved for human influenza vaccination in European Union. The mode of action of MF59 is not fully elucidated yet, but results from several years of investigation indicate that MF59 establishes an immunocompetent environment at injection site which promotes recruitment of immune cells, including antigen presenting cells (APCs), that are facilitated to engulf antigen and transport it to draining lymph node (dLN) where the antigen is accumulated. In vitro studies showed that MF59 promotes the differentiation of monocytes to dendritic cells (Mo-DCs). Since after immunization with MF59, monocytes are rapidly recruited both at the injection site and in dLN and appear to have a morphological change toward a DC-like phenotype, we asked whether MF59 could play a role in inducing differentiation of Mo-DC in vivo. To address this question we immunized mice with the auto-fluorescent protein Phycoerythrin (PE) as model antigen, in presence or absence of MF59. We measured the APC phenotype and their antigen uptake within dLNs, the antigen distribution within the dLN compartments and the humoral response to PE. In addition, using Ovalbumin as model antigen, we measured the capacity of dLN APCs to induce antigen-specific CD4 T cell proliferation. Here, we show, for the first time, that MF59 promotes differentiation of Mo-DCs within dLNs from intranodal recruited monocytes and we suggest that this differentiation could take place in the medullary compartment of the LN. In addition we show that the Mo-DC subset represents the major source of antigen-loaded and activated APCs within the dLN when immunizing with MF59. Interestingly, this finding correlates with the enhanced triggering of antigen-specific CD4 T cell response induced by LN APCs. This study therefore demonstrates that MF59 is able to promote an immunocompetent environment also directly within the dLN, offering a novel insight on the mechanism of action of vaccine adjuvants based on emulsions.

Indexed as

Adjuvants, ImmunologicAnimalsAntigensCell DifferentiationDendritic CellsFemaleInfluenza VaccinesMiceMice, Inbred C57BLMonocytesPolysorbatesSqualeneAdjuvants, ImmunologicAntigensInfluenza VaccinesMF59 oil emulsionPolysorbatesSqualene

Identifiers

PMID29088224
PMCPMC5663329
OpenAlexW2767110860

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.